<DOC>
	<DOCNO>NCT01699022</DOCNO>
	<brief_summary>Cyclofem® monthly injectable contraceptive contain 25 mg MPA 5 mg estradiol cypionate ( E2C ) , long act ester estradiol . The current study ass steady-state pharmacokinetics pharmacodynamics MPA E2 administration Cyclofem® provide critical information determine similar bioavailability Cyclofem Lunelle woman reside USA .</brief_summary>
	<brief_title>Pharmacokinetic Pharmacodynamic Study Cyclofem</brief_title>
	<detailed_description>Concept Foundation , international nonprofit organization base Bangkok , Thailand , give commercial right Cyclofem® World Health Organization ( WHO ) use internationally . The brand name Concept Foundation register internationally include Cyclofem® , Novafem® ( Pharmacia Pharmaceuticals , Peapack NJ , formerly ( Pharmacia Upjohn Kalamazoo , Michigan ) . The company launch product license Concept Foundation brand name , Lunelle™ US market . Lunelle™ approve Food Drug Administration ( FDA ) October , 2000 follow approximately 350,000 woman use product . However , follow acquisition Pharmacia Upjohn Pfizer due several production problem , Pfizer withdraw Lunelle™ US market . Concept Foundation license Sun Pharmaceutical Industries Ltd , Mumbai , India manufacture market Cyclofem® India develop country . US FDA approval Cyclofem® pivotal ultimate acceptance product many country rigorous standard apply FDA drug safety efficacy . This initial PK study first step road FDA approval ultimate goal expand access range method available woman public sector . Approval Cyclofem® US FDA would also allow reintroduction CICs US market .</detailed_description>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>CycloProvera</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>1 . Between 18 45 year age , inclusive ; 2 . In good health , evidence history procedure screening/enrollment visit 3 . Without clinically significant systemic disease ; 4 . Not risk pregnancy , undergone surgical sterilization 5 . Have regular menstrual cycle ( every 2135 day ) past two cycle ; 6 . Planning reside area least 7 month enrol study ; 7 . Willing able comply study procedures 8 . Have body mass index ( BMI ) 18 30 inclusive . 1 . Contraindications use Cyclofem® include : 1 . Smoking number cigarette per day woman &gt; 35 year old ( woman 34 yearsold turn 35 yearsold study ) , 2 . Symptoms chest pain shortness breath , 3 . Screening visit blood pressure &gt; 140/90 , ( subject hypertensive medication , good blood pressure control admit ) . 4 . Past current thrombophlebitis thromboembolic disorder , 5 . Past current cerebral vascular coronary artery disease 6 . History stroke , myocardial infarction ischemic heart disease complicate valvular heart disease 7 . Diabetes 8 . Past current carcinoma endometrium cervix vagina ; breast know suspect estrogendepended neoplasia , 9 . Headaches focal neurological symptom , 10 . Unexplained abnormal vaginal bleeding , 11 . Liver dysfunction disease , history hepatic adenoma carcinoma ; history cholestatic jaundice pregnancy jaundice prior hormonal contraceptive use include severe pruritus pregnancy , severe cirrhosis , active hepatitis ( defined aspartate aminotransferase ( AST SGOT ) ≥ 120 IU/L alanine aminotransferase ( ALT SGPT ) ≥ 135 IU/L ) clinically significant laboratory abnormality judge physician evaluate individual subject ) . 2 . Known hypersensitivity component Cyclofem® 3 . Have abnormal Pap smear past 12 month define : 1 . ASCUS without normal repeat Pap smear least 6 month later ; 2 . ASCUS positive reflex highrisk HPV testing ( ASCUS/HPV+ ) LSIL except colposcopy perform ( without biopsy ) find evidence highgrade disease ( CIN II worse ) unless treatment indicate per local standard care ; 3 . ASCH , atypical glandular cell , HSIL unless treatment receive followup least 6 month treatment show evidence disease ; malignant cell ; 4 . Current use rifampin , griseofulvin , phenytoin , carbamazepine , barbiturate , primidone ; 5 . Other condition , opinion investigator , would constitute contraindication participation study would compromise ability comply study protocol , major chronic illness include cancer , serious autoimmune disease major psychiatric disorder ( e.g . schizophrenia ) ; 6 . Current participation drug device study , study , opinion investigator , would jeopardize interpretation result study ; 7 . Active thyroid disease ( measure TSH level ≤0.3 mU/L ≥ 5 mU/L . Subjects thyroid disease good control thyroid medication admit .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Contraceptive</keyword>
	<keyword>Injectable</keyword>
</DOC>